| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/25/2023 | 60.94% | Rosenblatt | $27 → $30 | Maintains | Buy |
| 08/18/2023 | 60.94% | Rosenblatt | $27 → $30 | Maintains | Buy |
| 07/28/2023 | 28.76% | Barrington Research | → $24 | Reiterates | Outperform → Outperform |
| 07/27/2023 | 39.48% | Wedbush | → $26 | Reiterates | Outperform → Outperform |
| 07/27/2023 | 60.94% | Rosenblatt | $27 → $30 | Maintains | Buy |
| 07/20/2023 | 39.48% | Wedbush | → $26 | Reiterates | Outperform → Outperform |
| 07/13/2023 | 23.39% | Benchmark | → $23 | Reiterates | Buy → Buy |
| 07/13/2023 | 39.48% | Wedbush | → $26 | Reiterates | Outperform → Outperform |
| 07/13/2023 | 44.85% | Rosenblatt | → $27 | Reiterates | Buy → Buy |
| 07/12/2023 | 39.48% | Roth MKM | $26 → $26 | Reiterates | Buy → Buy |
| 05/02/2023 | 28.76% | Barrington Research | → $24 | Reiterates | → Outperform |
| 05/02/2023 | 23.39% | Benchmark | $22 → $23 | Maintains | Buy |
| 04/28/2023 | 44.85% | B. Riley Securities | $26 → $27 | Maintains | Buy |
| 04/28/2023 | 39.48% | Roth MKM | $24 → $26 | Maintains | Buy |
| 04/28/2023 | 34.12% | Wells Fargo | $22 → $25 | Maintains | Overweight |
| 04/28/2023 | 44.85% | Rosenblatt | $25 → $27 | Maintains | Buy |
| 04/25/2023 | 34.12% | Wedbush | $22 → $25 | Maintains | Outperform |
| 04/10/2023 | 39.48% | B. Riley Securities | $23 → $26 | Maintains | Buy |
| 04/05/2023 | 34.12% | Rosenblatt | → $25 | Reiterates | → Buy |
| 02/28/2023 | -24.89% | Goldman Sachs | $12 → $14 | Maintains | Sell |
| 02/23/2023 | 7.3% | Barrington Research | → $20 | Reiterates | → Outperform |
| 02/23/2023 | 1.93% | JP Morgan | $16 → $19 | Maintains | Neutral |
| 02/23/2023 | 34.12% | Rosenblatt | $22 → $25 | Maintains | Buy |
| 01/17/2023 | 18.03% | Rosenblatt | → $22 | Reiterates | → Buy |
| 12/05/2022 | 23.39% | B. Riley Securities | $20 → $23 | Maintains | Buy |
| 11/01/2022 | -14.16% | JP Morgan | $18 → $16 | Maintains | Neutral |
| 11/01/2022 | 12.66% | Wells Fargo | $26 → $21 | Maintains | Overweight |
| 10/10/2022 | -3.43% | JP Morgan | $19 → $18 | Maintains | Neutral |
| 10/06/2022 | 12.66% | Benchmark | $25 → $21 | Maintains | Buy |
| 07/18/2022 | 34.12% | Benchmark | $28 → $25 | Maintains | Buy |
| 06/21/2022 | 34.12% | B. Riley Securities | $30 → $25 | Maintains | Buy |
| 05/24/2022 | 34.12% | Rosenblatt | → $25 | Initiates Coverage On | → Buy |
| 04/29/2022 | 23.39% | MKM Partners | $25 → $23 | Maintains | Buy |
| 10/22/2021 | 44.85% | Wells Fargo | → $27 | Initiates Coverage On | → Overweight |
| 06/02/2021 | -0.21% | Goldman Sachs | $19.6 → $18.6 | Downgrades | Neutral → Sell |
| 04/23/2021 | 39.48% | Wedbush | $22 → $26 | Upgrades | Neutral → Outperform |
| 02/01/2021 | 34.12% | MKM Partners | $18 → $25 | Maintains | Buy |
| 01/25/2021 | -3.97% | Goldman Sachs | $15.6 → $17.9 | Downgrades | Buy → Neutral |
| 07/13/2020 | -3.43% | MKM Partners | $20 → $18 | Maintains | Buy |
| 04/28/2020 | -24.89% | Benchmark | → $14 | Upgrades | Hold → Buy |
| 04/24/2020 | -35.62% | Wedbush | $25 → $12 | Downgrades | Outperform → Neutral |
| 04/15/2020 | 7.3% | MKM Partners | $24 → $20 | Maintains | Buy |
| 03/18/2020 | 1.93% | B. Riley Securities | $26 → $19 | Maintains | Buy |
| 03/17/2020 | — | Benchmark | Downgrades | Buy → Hold | |
| 03/17/2020 | -19.53% | JP Morgan | $22 → $15 | Downgrades | Overweight → Neutral |
| 02/20/2020 | 34.12% | Wedbush | $22 → $25 | Maintains | Outperform |
| 02/13/2020 | 39.48% | B. Riley Securities | $30 → $26 | Reiterates | → Buy |
| 02/03/2020 | 18.03% | Wedbush | $28 → $22 | Maintains | Outperform |
| 01/29/2020 | 7.3% | Benchmark | $28 → $20 | Maintains | Buy |
| 11/01/2019 | — | Canaccord Genuity | Upgrades | Hold → Buy | |
| 02/25/2019 | — | Canaccord Genuity | Downgrades | Buy → Hold | |
| 10/26/2018 | 23.39% | Canaccord Genuity | $26 → $23 | Maintains | Buy |
What is the target price for Imax (IMAX)?
The latest price target for Imax (NYSE: IMAX) was reported by Rosenblatt on August 25, 2023. The analyst firm set a price target for $30.00 expecting IMAX to rise to within 12 months (a possible 60.94% upside). 29 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Imax (IMAX)?
The latest analyst rating for Imax (NYSE: IMAX) was provided by Rosenblatt, and Imax maintained their buy rating.
When is the next analyst rating going to be posted or updated for Imax (IMAX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Imax, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Imax was filed on August 25, 2023 so you should expect the next rating to be made available sometime around August 25, 2024.
Is the Analyst Rating Imax (IMAX) correct?
While ratings are subjective and will change, the latest Imax (IMAX) rating was a maintained with a price target of $27.00 to $30.00. The current price Imax (IMAX) is trading at is $18.64, which is out of the analyst's predicted range.